# Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

> **NCT06096038** · PHASE1,PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 33 (estimated)

## Conditions studied

- Head and Neck Cancer
- Relapse
- Recurrent
- Refractory Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Cell Therapy

## Key facts

- **NCT ID:** NCT06096038
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2026-09-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06096038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06096038, "Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06096038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*